Loading...
XNASPRCT
Market cap4.59bUSD
Jan 03, Last price  
84.30USD
1D
1.37%
1Q
16.02%
IPO
134.75%
Name

PROCEPT BioRobotics Corp

Chart & Performance

D1W1MN
XNAS:PRCT chart
P/E
P/S
33.67
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
136m
+81.55%
6,169,0007,717,00034,473,00075,014,000136,191,000
Net income
-106m
L+13.16%
-42,653,000-58,255,000-62,384,000-93,584,000-105,897,000
CFO
-108m
L+34.36%
-43,818,000-48,343,000-57,334,000-80,382,000-108,003,000
Earnings
Feb 25, 2025

Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
IPO date
Sep 15, 2021
Employees
428
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
136,191
81.55%
75,014
117.60%
Cost of revenue
113,588
66,910
Unusual Expense (Income)
NOPBT
22,603
8,104
NOPBT Margin
16.60%
10.80%
Operating Taxes
6,430
Tax Rate
79.34%
NOPAT
22,603
1,674
Net income
(105,897)
13.16%
(93,584)
50.01%
Dividends
Dividend yield
Proceeds from repurchase of equity
161,705
8,826
BB yield
-8.17%
-0.48%
Debt
Debt current
1,683
2,129
Long-term debt
103,703
101,292
Deferred revenue
Other long-term liabilities
517
1,779
Net debt
(151,836)
(121,476)
Cash flow
Cash from operating activities
(108,003)
(80,382)
CAPEX
(25,206)
(2,653)
Cash from investing activities
(25,206)
(2,653)
Cash from financing activities
167,795
3,612
FCF
(28,246)
(31,251)
Balance
Cash
257,222
221,859
Long term investments
3,038
Excess cash
250,412
221,146
Stockholders' equity
(454,488)
(348,681)
Invested Capital
814,961
624,020
ROIC
3.14%
0.38%
ROCE
6.27%
2.94%
EV
Common stock shares outstanding
47,255
44,400
Price
41.91
0.89%
41.54
66.09%
Market cap
1,980,457
7.38%
1,844,376
68.85%
EV
1,828,621
1,722,900
EBITDA
26,410
10,945
EV/EBITDA
69.24
157.41
Interest
3,995
5,183
Interest/NOPBT
17.67%
63.96%